IBSchek is a simple ELISA-based blood test that is highly predictive of an Irritable Bowel Syndrome (IBS) diagnosis based on the presence of 2 antibodies—anti-CdtB and anti-vinculin. In a study of more than 2,500 patients conducted in 180 centers around the USA, IBSchek was found to be more commonly positive in IBS compared to patients with Crohn’s disease, ulcerative colitis and celiac disease. These results confirmed that IBSchek is the only quick and reliable blood test for the diagnosis of IBS.
The Pathogenesis of IBS
With IBSchek, IBS may no longer be a diagnosis of exclusion. What we know today regarding acute gastroenteritis has helped Commonwealth Diagnostics International, Inc. develop the only quick and reliable diagnostic blood test that can provide a confident diagnosis for IBS.
An Expert’s Perspective
Validated biomarkers for an IBS diagnosis
It is now known that acute gastroenteritis can lead to IBS. Based on extensive human and animal research, the presence of an antibody to a toxin from gastroenteritis called cytolethal distending toxin B, as well as vinculin, a human protein commonly found in the nerves and the lining of the gut, are highly predictive of a diagnosis for IBS. With validated biomarkers, healthcare providers can now confidently diagnose certain mechanisms of IBS without excessive investigation.
The Published Clinical Review
Development and Validation of a Biomarker for Diarrhea-Predominant Irritable Bowel Syndrome in Human Subjects
Mark Pimentel, Walter Morales, Ali Rezaie, et al.
Click here to access the full-text version of the article.